Why did RBI deny banking licences to corporates again?, BFSI News, ET BFSI

[ad_1]

Read More/Less


The Reserve Bank of India has disappointed big corporates that are looking to enter the banking sector, as it kept in abeyance the proposal of its internal working group to allow large industrial houses in the sector.

RBI said it had accepted 21 recommendations with some modifications of the 33 proposed by the committee in November last year. The most contentious proposal by the five-member panel was to allow large corporate houses as promoters of banks after amendments to the Banking Regulation Act. Experts pointed that RBI would face challenges in supervising non-financial sector entities, and supervisory resources could be further strained.

Former RBI governor Raghuram Rajan and deputy governor Viral Acharya were foremost among the experts who had opposed the proposed move last year.

“The history of such connected lending is invariably disastrous – how can the bank make good loans when it is owned by the borrower? Even an independent regulator, with all the information in the world, finds it difficult to be in every nook and corner of the financial system to stop poor lending,” they said in a joint article. In August 2011, the then RBI Governor D. Subbarao said in one of his speeches, “by far the biggest apprehension is about self-dealing — that companies will use the bank as a private pool of readily available funds.”

The argument against

While corporates can bring in capital, business experience and managerial competence, the biggest risk of allowing industrial houses to promote banks is the conflict of interest. A bank is an intermediary which channels public deposits to borrowers. It was not easy for supervisors to prevent or detect self-dealing or connected lending as banks could hide connected party or related party lending behind complex company structures and subsidiaries or through lending to suppliers of promoters and their group companies. RBI also has had an unsatisfactory record in its role as the banking supervisor. Recent governance failures in private banks can be traced to a lack of independence within the board.

The current status

Individuals and companies, directly or indirectly connected with large industrial houses, can participate in the equity of a new private sector bank up to 10 per cent but without controlling interest in the bank. Such shareholders are not allowed to have any Director on the board of the bank on account of shareholder agreements or otherwise, according to the RBI Guidelines for ‘on tap’ Licensing of Universal Banks in the Private Sector issued in August 2016. A group with assets of Rs 5,000 crore or more with the non-financial business of the group accounting for 40 per cent or more in terms of total assets or in terms of gross income, will be treated as a large industrial house, the RBI said.

Tech disruption

The real transformation in banking is coming from tech companies. A core function of traditional banking, payments, has already been disrupted by fintech. Now, Big Tech is pushing the envelope in financial intermediation. Data is central to the digital economy. It’s given Big Tech an opening, leading to the so-called DNA (data-network-activities feedback loop) advantage. Navigating the risks here is the emerging regulatory challenge. In this situation, there’s no pressing need to add another risk in terms of allowing industrial houses to promote banks.



[ad_2]

CLICK HERE TO APPLY

SBI enters into co-lending arrangement with Capri Global Capital

[ad_1]

Read More/Less


With an aim to boost MSME lending, the country’s largest bank, the State Bank of India (SBI), has entered into a co-lending arrangement with Capri Global Capital (CGCL). This association will offer strategic and customised financing solutions to the underserved MSMEs of the country in line with RBI guidelines.

Dinesh Khara, Chairman, SBI said, “Banks are the backbone of India’s economic growth and as the country pivots to sustainable growth, the banking sector will have to accelerate MSME lending. To improve the credit to the underserved and unserved, we are happy to associate with Capri Global Capital. We believe this collaboration will provide the nimble footedness of NBFC and quality credit to the right set of the population which will further deepen lending to MSMEs through the last mile connect. We are also confident that, in days to come, co-lending can generate employment opportunities through MSMEs which can translate into the country’s GDP growth.”

The RBI had issued guidelines on the co-lending scheme for banks and NBFCs for priority sector lending to improve the flow of credit to unserved and underserved sectors of the economy and to make funds available to borrowers at an affordable cost. The co-lending model aims to give the borrower the best interest rate and better reach.

[ad_2]

CLICK HERE TO APPLY

RBI gives approval to LIC to hike stake in Kotak Bank to 9.99%

[ad_1]

Read More/Less


The Reserve Bank of India has given its approval to Life Insurance Corporation of India to raise its stake in Kotak Mahindra Bank to 9.99 per cent.

“Kotak Mahindra Bank has received an intimation from LIC stating that the RBI had granted its approval to LIC for increasing its holding in the Bank up to 9.99 per cent of the paid-up equity share capital of Bank, subject to compliance with the provisions of the Master Direction on ‘prior approval for acquisition of shares or voting rights in private sector banks’ dated November 19, 2015, and Master Direction on ‘ownership in private sector banks’ dated May 12, 2016, provisions of the applicable regulations issued by the Securities and Exchange Board of India, provisions of the Foreign Exchange Management Act, 1999 and any other guidelines/regulations and statutes, as applicable,”the private sector lender said in a stock exchange filing on Monday.

The approval is valid for a period of one year, it further said.

LIC currently holds 4.96 per cent stake in the bank as of September 30.

[ad_2]

CLICK HERE TO APPLY

ICICI Bank Revises Interest Rates On FD: Check Latest Rates Here

[ad_1]

Read More/Less


ICICI Bank FD Rates

With effect from 16th November 2021, ICICI Bank has revised its interest rates on domestic term deposits of less than Rs 2 Cr maturing in 7 days to 10 years. Following the most recent revision, the general public will now get the following interest rates on their fixed deposits.

Tenure Interest rates (p.a.) for deposits of less than Rs 2 Cr. Interest rates (p.a.) for deposits of Rs. 2 Cr and above less than Rs. 5 Cr
7 days to 14 days 2.50% 2.75%
15 days to 29 days 2.50% 2.75%
30 days to 45 days 3.00% 3.00%
46 days to 60 days 3.00% 3.00%
61 days to 90 days 3.00% 3.15%
91 days to 120 days 3.50% 3.15%
121 days to 150 days 3.50% 3.15%
151 days to 184 days 3.50% 3.15%
185 days to 210 days 4.40% 3.65%
211 days to 270 days 4.40% 3.65%
271 days to 289 days 4.40% 3.90%
290 days to less than 1 year 4.40% 3.90%
1 year to 389 days 4.90% 4.05%
390 days to 4.90% 4.05%
15 months to 4.90% 4.15%
18 months to 2 years 5.00% 4.25%
2 years 1 day to 3 years 5.15% 4.50%
3 years 1 day to 5 years 5.35% 4.70%
5 years 1 day to 10 years 5.50% 4.70%
5 Years (80C FD) 5.35% NA
Source: Bank Website. W.e.f. November 16, 2021 W.e.f. November 29, 2021

ICICI Bank FD Rates For Senior Citizens

ICICI Bank FD Rates For Senior Citizens

Senior citizens will continue to get an additional rate of 0.50% over and above the card rate applicable to the general public across all tenors. On the other hand, ICICI Bank also offers a special fixed deposit scheme to senior citizens named ICICI Bank Golden Years FD. Under this scheme, senior citizens would get an additional interest rate of 0.30% per annum on their deposits maturing in 5 years and up to 10 years.

The effective interest rate under the scheme would be an additional 0.30 percent per annum over and above the prevailing additional rate of 0.50 percent per annum on single deposits of less than Rs. 2 crores made by a resident Indian senior citizen for a limited time till 8th April 2022. Here are the latest interest rates on fixed deposits of ICICI Bank for senior citizens.

Tenure Interest rates (p.a.) for deposits of less than Rs 2 Cr. Interest rates (p.a.) for deposits of Rs. 2 Cr and above less than Rs. 5 Cr
7 days to 14 days 3.00% 2.75%
15 days to 29 days 3.00% 2.75%
30 days to 45 days 3.50% 3.00%
46 days to 60 days 3.50% 3.00%
61 days to 90 days 3.50% 3.15%
91 days to 120 days 4.00% 3.15%
121 days to 150 days 4.00% 3.15%
151 days to 184 days 4.00% 3.15%
185 days to 210 days 4.90% 3.65%
211 days to 270 days 4.90% 3.65%
271 days to 289 days 4.90% 3.90%
290 days to less than 1 year 4.90% 3.90%
1 year to 389 days 5.40% 4.05%
390 days to 5.40% 4.05%
15 months to 5.40% 4.15%
18 months to 2 years 5.50% 4.25%
2 years 1 day to 3 years 5.65% 4.50%
3 years 1 day to 5 years 5.85% 4.70%
5 years 1 day to 10 years 6.30% 4.70%
5 Years (80C FD) 5.85% NA
Source: Bank Website. W.e.f. November 16, 2021 W.e.f. November 29, 2021

ICICI Bank NRO & NRE Deposits Interest Rates

ICICI Bank NRO & NRE Deposits Interest Rates

ICICI Bank has also updated its interest rates on domestic, NRO, and NRE deposits of Rs 5 crore and above with a premature withdrawal facility, which entered into force on November 29, 2021.

Tenure Rs 5 Cr to Rs 5.10 Cr to Rs 24.90 Cr to Rs 25 Cr to Rs 100 Cr to Rs 250 Cr to More than Rs 500 Cr
7 days to 14 days 2.75 2.75 2.75 2.75 2.75 2.75 2.75
15 days to 29 days 2.75 2.75 2.75 2.75 2.75 2.75 2.75
30 days to 45 days 2.75 3 2.75 3 3 3 3
46 days to 60 days 2.75 3 2.75 3 3 3 3
61 days to 90 days 2.85 3.15 2.85 3.15 3.15 3.15 3.15
91 days to 120 days 2.85 3.15 2.85 3.15 3.15 3.15 3.15
121 days to 150 days 2.85 3.15 2.85 3.15 3.15 3.15 3.15
151 days to 184 days 2.85 3.15 2.85 3.15 3.15 3.15 3.15
185 days to 210 days 3 3.65 3 3.65 3.65 3.65 3.65
211 days to 240 days 3 3.65 3 3.65 3.65 3.65 3.65
241 days to 270 days 3 3.65 3 3.65 3.65 3.65 3.65
271 days to 300 days 3 3.9 3 3.9 3.9 3.9 3.9
301 days to 330 days 3 3.9 3 3.9 3.9 3.9 3.9
331 days to 3 3.9 3 3.9 3.9 3.9 3.9
1 year to 389 days 3.25 4.05 3.25 4.05 4.05 4.05 4.05
390 days to 3.25 4.05 3.25 4.05 4.05 4.05 4.05
15 months to 3.25 4.15 3.25 4.15 4.15 4.15 4.15
18 months to 2 years 3.25 4.25 3.25 4.25 4.25 4.25 4.25
2 years 1 day to 3 years 3.25 4.5 3.25 4.5 4.5 4.5 4.5
3 years 1 day to 5 years 3.25 4.7 3.25 4.7 4.7 4.7 4.7
5 years 1 day to 10 years 3.25 4.7 3.25 4.7 4.7 4.7 4.7
Rate of Interest (% p.a.) w.e.f November 29, 2021



[ad_2]

CLICK HERE TO APPLY

SBI enters co-lending agreement with Capri Global Capital Ltd, BFSI News, ET BFSI

[ad_1]

Read More/Less


State Bank of India has entered into a co-lending agreement with Capri Global Capital Ltd (CGCL) to boost MSME lending. The two parties have signed a Memorandum of Understanding to create multiple co-lending opportunities for the financial empowerment of the MSMEs, which aims to provide further impetus to financial inclusion in the country, the bank said in a release.

Dinesh Khara, Chairman, SBI said, “To improve the credit to the underserved and unserved, we are happy to associate with Capri Global Capital. We believe this collaboration will provide the nimble footedness of NBFC and quality credit to the right set of the population which will further deepen lending to MSMEs through the last mile connect.”

RBI had issued guidelines on the co-lending scheme for banks and NBFCs for priority sector lending to improve the flow of credit to unserved and underserved sectors of the economy, and make funds available to borrowers at an affordable cost.

Follow and connect with us on , Facebook, Linkedin



[ad_2]

CLICK HERE TO APPLY

7 Intraday Cash Buy/Sell Recommendations Of Angel Broking

[ad_1]

Read More/Less


Investment

oi-Roshni Agarwal

|

Angel One previously known as Angel Broking is the largest independent full-service retail brokerage firm. The firm based on its proprietary research aims to provide exhaustive and accurate data to every online share trader. Likewise, it comes up with stock recommendations for intra-day trade as well as long term picks.

7 Intraday Cash Buy/Sell Recommendations Of Angel Broking

7 Intraday Cash Buy/Sell Recommendations Of Angel Broking

For today i.e. November 29, 2021, after the markets have recovered some of the last week’s whopping losses to the tune of 4% on the Sensex, are trading on a positive note. Sensex at around 12:49 pm traded firm with gains of over 400 points, while Nifty is at 17,128 points.

Here are the intra-day buy and sell recommendations of Angel Broking:

Intraday Cash Buy ideas

Apollo Hospitals: Buy Apollo Hospitals in the price range of Rs. 5787-5795 for a target price of Rs. 6042. Stop loss suggested for the trade is Rs. 5648.7

HCL Tech: Buying price range -Rs. 1132-1133 for a target price of Rs. 1195 with a SL of Rs. 1100

Power Grid: Buy Power Grid at the rate of Rs. 201.45-202.45 for a target of Rs. 210. Stop loss given for the suggested trade is Rs. 197.8

Pfizer: Buying initiation range @ Rs. 5380-5390; target price – Rs. 5600. Stop loss – Rs. 5275

IndiaMart: Buy IndiaMart for a price target of Rs. 7527 in the price range of Rs. 7302-7307, SL- Rs. 7177.

Reliance Industrial Infra: For a price target of Rs. 729, buy this scrip in the range of Rs. 694.1-696.1; SL- Rs. 677

Intraday Cash Sell ideas:

Power Finance Corporation: Sell PFC @ Rs. 117.7-118.7 for a target of Rs. 114; SL- Rs. 119.9

GoodReturns.in



[ad_2]

CLICK HERE TO APPLY

“BUY” This Mid Cap Auto Stock With A Target Price of Rs. 2000: HDFC Securities

[ad_1]

Read More/Less


Q2FY22 results of Escorts Ltd

According to the brokerage “Escorts reported a subdued set of numbers in Q2FY22 as irregular and uneven rainfall impacted demand for tractors. Operating income stood at Rs 1662cr, growing marginally. Agri Machinery revenues decreased 6% YoY to Rs 1241 due to a 14% YoY decline in tractor volumes offset partially by an improved realisation of 9% to Rs 5.9 lakh/unit. Construction Equipment(ECE) division revenue surged 58% YoY to Rs 249cr, as sales volume increased 31% to 1074 units. Railway Equipment Division (RED) recorded a topline of Rs 170cr vs. Rs 160cr in Q2FY21.”

The brokerage in its research report has claimed that the company’s “EBITDA fell 30% YoY to Rs 210cr while EBITDA margin contracted 570bps to 12.6% on account of the adverse impact of rising commodity prices, negative operating leverage, and low volumes. The company reported a PAT of Rs 177cr, a decline of 23% YoY. For the month of Oct, its exports business recorded a robust sales growth of 58% YoY to 765 units v/s 484 in Oct’21. However, in the domestic market, there was a decline of 3%. The sales volume for the domestic business for the month of October stood at 12749 v/s 13180 in Oct’21. Escorts Construction Equipment sales grew by 15.8% in Oct’21. It sold 462 machines, as against 399 machines sold in Oct/20.”

Key triggers for future performance according to HDFC Securities

Key triggers for future performance according to HDFC Securities

The brokerage has reported that “The Board of Escorts approved a preferential allotment of 93.6 lakh shares to Japan’s Kubota Corporation at Rs 2000/share for a total consideration of Rs 1873cr. This would trigger an open offer by Kubota for a 26% stake in Escorts. Assuming that the open offer is successful and the entire treasury shares (held in Escorts Benefit & Welfare trust) are cancelled Kubota would have a 53.5% stake in the company, which could further increase as it evaluates to merge its two JVs in India with Escorts. The Board also proposed to increase the limit on the maximum number of directors of the Company from 15 to 18 as it plans to have four directors nominated by Kubota (from two currently), four nominated by the promoters and eight independent directors.”

HDFC Securities has also commented in its research report that “Investors looking for short-term gain can buy the stock at a current price of ~Rs 1820. The acceptance ratio of shares in the open offer can be between 60-100% vs the theoretical ratio of 51%. As per the Sep-2021 shareholding pattern, FIIs hold a 21.5% stake in the company, DII holds a 7.6%, HNIs (upto Rs 2 lakh nominal value) hold 7.2% and other retail shareholders hold 12.7% stake. We expect institutions could tender 40- 50% of their holdings and the overall acceptance ratio to be between 75-85%. Existing Promoter i.e. the Nanda Family are not selling any shares and continues to remain fully invested in the Company. Assuming that the open offer is completed in 3 months and there is full acceptance of shares, an investor can earn an annualized return of ~40%.”

“We continue to remain bullish on the prospects of the company over the medium term and even if the price falls post the open offer investors need not panic and can continue to hold on to the stock given the MNC pedigree. Kubota’s plan to acquire a majority stake in Escorts lends credence to its commitment to this partnership. Kubota is likely to leverage India’s low-cost base in sourcing products like farm implements, construction equipment and components which could drive strong growth for Escorts in the medium to long term” said HDFC Securities.

Buy Escorts Ltd with a target price of Rs. 2000

Buy Escorts Ltd with a target price of Rs. 2000

According to the brokerage’s call “The company continues to be net debt-free with sufficient available liquidity for growth. Also, the Kubota induction as a majority promoter and outlook of recovery in railway/construction space is encouraging. We expect Escorts Revenue/EBITDA/PAT to grow at 9/6/6% CAGR over FY21-FY24, led by improvement in domestic volumes and increased exports. At the current price, the stock trades at 18.6x Sep-23 EPS estimate which is not expensive given its strong medium term prospects post-Kubota becoming the majority stakeholder.”

“We believe investors can buy the stock in the band of Rs 1800-1830 and add on dips to Rs 1650-1680 band (17x Sep-23E EPS) for a base case fair value of Rs 2000 (20.5x Sep-23E EPS) over the next 2 quarters. Investors can offer their shares in the open offer expected over the next few months at Rs 2000. Post the completion of the offer we expect the stock price to react downwards, but over the medium term, the open offer price may be exceeded” the brokerage claimed.

Disclaimer

Disclaimer

The stock has been picked from the brokerage report of HDFC Securities Limited. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution. Greynium Information Technologies, the author, and the brokerage house are not liable for any losses caused as a result of decisions based on the article.



[ad_2]

CLICK HERE TO APPLY

IBC to get welcome cross-border teeth, BFSI News, ET BFSI

[ad_1]

Read More/Less


The government’s reported move to adopt a legal framework for cross-border insolvency resolution is welcome. It would enlarge the scope for debt recovery, provide comfort to foreign investors and improve the ease of doing business here. In a rapidly globalising economy, the impact of any business failure transcends national boundaries. An insolvent debtor can have assets and creditors in more than one country.

Rightly, India wants to adopt the UNCITRAL Model Law of Cross Border Insolvency, 1997, aligning with global practice. It will enable foreign creditors to start or participate in insolvency proceedings in India, sell or attach assets of the debtor to recover their loans. Similarly, Indian creditors will receive assistance from other countries that have adopted this model law. Any incentive to create assets overseas to escape domestic creditors would disappear. The UN model law gives precedence to domestic proceedings and protection of public interest. It also fosters cooperation between domestic and foreign courts and insolvency professionals. India’s draft legal framework, to be a part of the Insolvency and Bankruptcy Code (IBC), excludes banking and financial services, as well as pre-packs for small businesses.

The draft distinguishes between foreign main proceedings and foreign non-main proceedings to determine the level of control that a jurisdiction has over the insolvency resolution process, and the extent of relief that the National Company Law Tribunal can grant. NCLT’s adjudication capacity must be beefed up, if it has to work on par with foreign counterparts. Lenders (read Indian banks) too must act swiftly at the first sign of distress to prevent other, foreign, creditors from initiating insolvency proceedings.



[ad_2]

CLICK HERE TO APPLY

Motilal Oswal Recommends To ‘Buy’ This Pharma Stock For +30% Upside, While The Equity Market Is Down For Omicron Coronavirus

[ad_1]

Read More/Less


Target Price

Target Price

The Current Market Price (CMP) of Solara Active Pharma is Rs. 1169. The brokerage firm, Motilal Oswal has estimated a Target Price for the stock at Rs. 1520. Hence the stock is expected to give a 30% return, in a Target Period of 1 year.

Stock Outlook
Current Market Price (CMP) Rs. 1169
Target Price Rs. 1520
1 year returns 30.00%

Company performance

Company performance

The company’s sales stood at Rs. 16.2 b, in FY 2021, and Motilal Oswal is expecting Rs. 23.6 b sales in FY22 and Rs. 27.5 b sales in FY 23. on the other hand, adjusted PAT was Rs. 2.2 b in FY 21; the firm is anticipating Rs. 3.6 b PAT in FY 22, and a Rs. 4.5 b PAT in FY 23. On account of reduced demand, Ibuprofen prices had corrected by 20-25% over the past 5-6 months, affecting the operating margins from this product. However, prices at the API level are now stable.

Comments by Motilal Oswal

Comments by Motilal Oswal

Maintaining a buy rating Motilal Oswal said, “SOLARA is progressing well on building a niche product pipeline and broadening its presence in the regulated and ROW markets.” The brokerage firm added, “Additionally, SOLARA is progressing well on ramping up the production of Isobutyl Benzene, a key RM used in the manufacturing of Ibuprofen. This would offset the drop in profitability, to some extent, over the near-to#medium term.”

About the company

About the company

Solara Active Pharma Sciences is a dynamic, entrepreneurial, and customer-oriented API manufacturer. They have 140+ scientists working at their 2 R&D Centers, and 5 API manufacturing facilities armed with global approvals and 2 dedicated R&D facilities.

Disclaimer

Disclaimer

The above stock was picked from the brokerage report of Motilal Oswal. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution. Greynium Information Technologies, the author, and the brokerage house are not liable for any losses caused as a result of decisions based on the article.



[ad_2]

CLICK HERE TO APPLY

Motilal Oswal Recommends To ‘Buy’ This Pharma Stock For +30% Upside, While The Equity Market Is Down For Omicron Coronavirus

[ad_1]

Read More/Less


Target Price

The Current Market Price (CMP) of Solara Active Pharma is Rs. 1169. The brokerage firm, Motilal Oswal has estimated a Target Price for the stock at Rs. 1520. Hence the stock is expected to give a 30% return, in a Target Period of 1 year.

Stock Outlook
Current Market Price (CMP) Rs. 1169
Target Price Rs. 1520
1 year returns 30.00%

Company performance

Company performance

The company’s sales stood at Rs. 16.2 b, in FY 2021, and Motilal Oswal is expecting Rs. 23.6 b sales in FY22 and Rs. 27.5 b sales in FY 23. on the other hand, adjusted PAT was Rs. 2.2 b in FY 21; the firm is anticipating Rs. 3.6 b PAT in FY 22, and a Rs. 4.5 b PAT in FY 23. On account of reduced demand, Ibuprofen prices had corrected by 20-25% over the past 5-6 months, affecting the operating margins from this product. However, prices at the API level are now stable.

Comments by Motilal Oswal

Comments by Motilal Oswal

Maintaining a buy rating Motilal Oswal said, “SOLARA is progressing well on building a niche product pipeline and broadening its presence in the regulated and ROW markets.” The brokerage firm added, “Additionally, SOLARA is progressing well on ramping up the production of Isobutyl Benzene, a key RM used in the manufacturing of Ibuprofen. This would offset the drop in profitability, to some extent, over the near-to#medium term.”

About the company

About the company

Solara Active Pharma Sciences is a dynamic, entrepreneurial, and customer-oriented API manufacturer. They have 140+ scientists working at their 2 R&D Centers, and 5 API manufacturing facilities armed with global approvals and 2 dedicated R&D facilities.

Disclaimer

Disclaimer

The above stock was picked from the brokerage report of Motilal Oswal. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution. Greynium Information Technologies, the author, and the brokerage house are not liable for any losses caused as a result of decisions based on the article.



[ad_2]

CLICK HERE TO APPLY

1 23 24 25 26 27 16,278